Healthcare / BiotechnologyNasdaqGM
$15.55
-0.39 (-2.45%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-11.9M · quality 48.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
61/100
B
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$802M
P/E
7.0x
↓EV/EBITDA
5.0x
↓ROE
35.7%
↑Gross Margin
N/A
•Debt/Equity
0.14
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2012–2025 · 13 años de histórico normalizado
Revenue CAGR
-1.5%
FCF CAGR
—
FCF margin
221.9%
FCF / Net income
2.25x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $107.5M · net income $105.9M · FCF $238.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||
| Revenue | $107.5M | $107.5M | $64.4M | $57.4M | $51.3M | $55.3M | $71.9M | $73.4M | $60.4M | $15.4M | $48.6M | $42.1M | $11.7M | $226000.00 | $130.1M |
| Net Income | $105.9M | $105.9M | $-56.4M | $-55.2M | $872.1M | $-199.4M | $-278.0M | $-236.5M | $-215.5M | $-285.4M | $-190.7M | $-182.2M | $-237.0M | $-156.3M | $-9.6M |
| EBITDA | $134.5M | $134.5M | $-38.5M | $-42.7M | $-79.4M | — | — | — | $-235.6M | $-256.1M | $-177.3M | $-178.9M | $-229.3M | $-153.6M | $-6.3M |
| EPS | 2.06 | 2.06 | -1.15 | -1.00 | 11.85 | -2.87 | -4.46 | -4.25 | — | — | — | — | — | — | — |
| Operating Margin | -3.4% | -3.4% | -65.9% | -92.8% | -154.1% | -466.1% | -414.2% | -343.1% | -395.5% | -1690.6% | -371.0% | -431.8% | -1989.6% | -69152.2% | -7.4% |
| Net Margin | 98.5% | 98.5% | -87.6% | -96.1% | 1698.5% | -360.6% | -386.9% | -322.1% | -357.0% | -1855.0% | -391.9% | -432.6% | -2028.0% | -69152.2% | -7.4% |
| Balance Sheet | |||||||||||||||
| Debt/Equity | 0.14 | 0.14 | 0.28 | 0.23 | 0.12 | -1.82 | -2.04 | -2.03 | -8.81 | 1.94 | — | — | — | — | — |
| Current Ratio | 13.14 | 13.14 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||
| Free Cash Flow | $238.5M | $238.5M | $-11.9M | $-29.5M | $-187.6M | — | — | — | — | — | $-101.1M | $-171.5M | — | — | — |
| Returns | |||||||||||||||
| ROE | 35.7% | 35.7% | -32.1% | -25.9% | 197.4% | 58.9% | 91.5% | 105.6% | 417.8% | -247.8% | -54.4% | -75.0% | -81.8% | 917.4% | 137.0% |
| Valuation | |||||||||||||||
| P/E | 6.97 | 6.97 | — | — | 0.95 | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 5.02 | 5.02 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 2.70 | 2.70 | 2.59 | 2.69 | 1.87 | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||
| Revenue Growth | 66.9% | 66.9% | 12.1% | 11.8% | — | -23.0% | -2.1% | 21.6% | 292.4% | -68.4% | 15.5% | 260.4% | 5071.7% | -99.8% | — |
| EPS Growth | 279.1% | 279.1% | -15.0% | -108.4% | — | 35.7% | -4.9% | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-12.5%
EPS terminal req.
$1.38
Spread vs growth
291.6%
5Y implied EPS CAGR
-4.1%
EPS terminal req.
$1.67
Spread vs growth
283.2%
10Y implied EPS CAGR
2.7%
EPS terminal req.
$2.69
Spread vs growth
276.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+39.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.15 → 2.06
Residual
+39.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.